Reconciling environment-mediated metabolic heterogeneity with the oncogene-driven cancer paradigm in precision oncology
(2020) Seminars in Cell and Developmental Biology — Vol. 98, p. 202-210 (2020)
Files
YSCDB_2018_118_Revision1_V0.pdf
Open Access - Adobe PDF
- 1.52 MB
Details
- Authors
- Abstract
- Precision oncology is the practice of matching one therapy to one specific patient, based on particular genetic tumor alterations, in order to achieve the best clinical response. Despite an expanding arsenal of targeted therapies, many patients still have a poor outcome because tumor cells show a remarkable capacity to develop drug resistance, thereby leading to tumor relapse. Besides genotype-driven resistance mechanisms, tumor microenvironment (TME) peculiarities strongly contribute to generate an intratumoral phenotypic heterogeneity that affects disease progression and treatment outcome. In this Review, we describe how TME-mediated metabolic heterogeneities actively participate to therapeutic failure. We report how a lactate-based metabolic symbiosis acts as a mechanism of adaptive resistance to targeted therapies and we describe the role of mitochondrial metabolism, in particular oxidative phosphorylation (OXPHOS), to support the growth and survival of therapy-resistant tumor cells in a variety of cancers. Finally, we detail potential metabolism-interfering therapeutic strategies aiming to eradicate OXPHOS-dependent relapse-sustaining malignant cells and we discuss relevant (pre)clinical models that may help integrate TME-driven metabolic heterogeneity in precision oncology.
- Affiliations
Citations
Vander Linden, C., & Corbet, C. (2020). Reconciling environment-mediated metabolic heterogeneity with the oncogene-driven cancer paradigm in precision oncology. Seminars in Cell and Developmental Biology, 98, 202-210. https://doi.org/10.1016/j.semcdb.2019.05.016 (Original work published 2020)